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Interferon plus tamoxifen treatment for advanced breast cancer: in vivo
biologic effects of two growth modulators
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Summary The effects of interferon-a (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer
were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and
growth factor expression were evaluated. Seven patients with advanced, heavily pretreated, breast cancer with
accessible disease, underwent biopsy prior to and after sequential treatment with IFN and IFN plus TMX.
Clinically 4/7 patients responded to treatment with one complete and three partial remissions. Apart from the
favourable response rate the sequential in vivo changes in expression of tumour variables were of considerable
interest.
IFN treatment consistently increased the expression of the estrogen receptor (ER) and of the estrogen
regulated protein P24 while decreasing the expression of the proliferation associated antigen Ki-67. Addition
of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in
progesterone receptor (PR) expression.
When the effect of either IFN or IFN plus TMX on the expression of two growth factors was assessed they
were found to be somewhat variable. While PDGF expression tended to be suppressed, there was no clinical
correlation with response to therapy. TGFP expression was found in all patients prior to treatment and while
all non-responders showed reduction of TGFP following treatment, the alterations were variable amongst
responders (including two patients with increased expression, one with no change, and one with decreased
expression).
It is concluded that both IFN and TMX exert multiple effects on the expression of tumour biologic
variables and that while the study confirmed some of the predictions from in vitro models, the in vivo effect are
more complex than has been appreciated from the models. From the clinical point of view, it might be
expected that treatment which enhances the expression of ER in tumours should have a positive effect on the
response to TMX.
Patients with advanced or metastatic breast cancer continue
to pose major therapeutic dilemmas for the practising
oncologist. Despite advances in the detection and treatment
of early stage disease, patients with advanced breast cancer
almost invariably die of the illness despite fairly frequent
responses to various treatment modalities (Henderson, 1987).
Additions to and substitutions of one or other
chemotherapeutic agent/s in conventional dose combination
chemotherapy has moreover failed to produce any further
substantial improvement in either response rate or response
duration (Coates et al., 1987).
Since the aim of treatment for patients with metastatic
disease is palliative, an important consideration is therapy
related toxicity. Amongst the palliative therapies, there is no
doubt that hormonal manipulation remains the approach
with the least treatment related morbidity and mortality.
Hormonally based treatment is however limited both as to
the proportion of patients responding and the duration of
response (Byer et al., 1979; Powles et al., 1984; Bezwoda et
al., 1991). While a number of new hormonal agents have
become available over the last few years it seems unlikely
that there will be major differences among any of them in
regard to either of these limitations. It would seem
reasonable however to explore approaches which might inc-
rease the effectiveness of hormone based treatment from
either the response rate or response duration point of
view.
Although interferon appears to have limited clinical effect
as a single agent it has interesting in vitro effects on various
breast cancer derived, estrogen responsive, cell lines including
MCF7 and ZR 75 cells. Alpha interferon has been shown to
increase estrogen receptor (ER) expression, and to have a
synergistic effect together with tamoxifen (TMX) in inhibiting
MCF-7 cell growth (Bezwoda & Meyer, 1990). Other authors
have reported similar effects with a interferon using the ZR
75 cell line (Van den Berg et al., 1987) and with P-interferon
using other breast cancer derived cell lines (Sica et al.,
1987).
In view of the potentially favourable effects of alpha-
interferon on both ER expression and response to tamoxifen
we performed a small pilot trial utilising interferon with
tamoxifen in patients with locally advanced metastatic breast
cancer. This study gave the opportunity to examine the
effects of these agents on in vivo tumour biology.
Methods
Premenopausal and postmenopausal patients were considered
eligible for entry to the trial if they had informed consent,
had evaluable disease, metastatic skin or soft tissue lesions
suitable for biopsy, had failed conventional cytotoxic
chemotherapy, and had no prior exposure to hormonal
manipulation. Recruitment began in June 1990 and ended 12
months later.
All patients underwent initial biopsy by means of a der-
matological punch biopsy or cytologic examination by fine
needle aspiration and were then started on interferon-x 2b
(Intron A - Scherag S.A.; IFNa) 3 million units sub-
cutaneously three times per week. Fourteen days later
patients underwent a second biopsy, and tamoxifen 20mg
per day by mouth was added to the treatment. Fourteen days
later a third biopsy was performed.
Response was assessed on the basis of criteria proposed by
the Eastern Co-operative Oncology Group (Hayward et al.,
1979). Toxicity assessment was by WHO criteria. Therapy
with both agents was continued until treatment failure occur-
red.
Biopsy specimens were flash frozen and stored at - 135°C
until use. ER immunocytochemistry, using the Abbot (Abbot
Laboratories) ER-ICA kit was performed according to the
manufacturers instructions. The monoclonal antibody to PR
was obtained from Transbio (Transbio, Paris, France). P24
antibody was a kind gift from Dr W. McGuire, San Antonio,
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Texas. The methods used and specificity of the staining reac-
tions have been previously described (Seymour et al., 1990a;
Seymour et al., 1990b; Seymour et al., 1990c).
Monoclonal antibody to platelet derived growth factor bb
(PDGF BB) was obtained from Promega (Promega Labora-
tories, Madison Wis., USA). The anti-PDGF aa antibody
was a monospecific, polyclonal antibody (British Biotech-
nology, Abingdon, UK).
The antibody against TGFa was a polyclonal antibody
(British Biotechnology) which has neutralising activity
against TGFP1, and TGFP2 and which reacts with both
isoforms of this growth factor on Western blotting. This
antibody has been shown in our laboratories to give consis-
tent staining of MCF7 cells (with the intensity of the staining
increasing on exposure of the cells to tamoxifen). The neu-
tralising activity of this anti-TGFP antibody has also been
confirmed in our laboratories and hence staining is thought
to represent an active form of TGFJ. This antibody does not
show any cross reactivity with acidic or basic fibroblast
growth factors (FGFs), platelet derived growth factor
(PDGF) or epidermal growth factor (EGF).
The immunocytochemical techniques used a standard
avidin-biotin technique (ABC kit, Vectastain Laboratories).
All immunocytochemical determinations were performed in a
single run, using picric acid-formaldehyde fixed preparations.
Positive controls included tissues processed in the same man-
ner as the experimental tissue and known to stain positively
for the appropriate determinant. Negative controls followed
all the steps used for the immunocytochemical determina-
tions but substituting normal (non-immune) immunoglobulin
from the appropriate species for the primary antibody.
Specimens were examined by light microscopy and scored
according to number of cells positive and intensity of stain-
ing. The scoring system used for ER, PR and P24 was the
H-score method as recommended by the manufacturers of
the ER-ICA kit. TGFP and PDGF bb were graded on a scale
of 0-5, and PDGF aa on a scale of 0-500. Ki 67 was
expressed as a percentage of cells showing positive stain-
ing.
In all cases there was concordance between multiple speci-
mens from the same tumour area. Repeat biopsies were
carried out from the same anatomical area as the original
biopsy, avoiding, however, the site previously subjected to
biopsy induced trauma.
Results
Seven patients were eligible for entry to the trial. Six patients
were premenopausal and had previously failed conventional
cytotoxics, and three of the six had failed second line
chemotherapy as well. One patient was post menopausal and
was deemed suitable for primary hormonal manipulation.
The mean age of the patients was 44 years with range 25-53
years. All patients had locally recurrent disease, usually
extensive and four had concurrent bone metastases. One
patient had extensive hepatic metastases. No patient had any
significant drug related symptoms or morbidity related to
biopsies. Further patient details and tumour biologic
variables at baseline assessment are shown in Table I.
Four of the seven patients (57%) responded, of which one
(14%) was a complete response. Two of the four responders
had early minor responses to IFN prior to addition of TMX
to the treatment regimen. The response duration ranged from
4 weeks to 32 weeks. Three patients had no initial response
to therapy. Toxicity from IFN was minimal at the doses used
(Table II). Flu-like symptoms and fever when they occurred
were readily controlled with the use of paracetamol.
At baseline evaluation 5/7 patients were ER positive and
four were PR positive as well. All of the responses occurred
among the ER positive patients, although one patient who
was both ER and PR positive failed to respond. All of the
ER positive patients, including the non-responder, showed an
increase in the intensity of ER staining after IFNa. Of the
three responders who were PR positive, one increased, one
decreased and one showed no change in PR expression after
interferon, but all increased PR expression after TMX (Table
III).
All of the responding patients were also initially P24
positive and all showed an increase in P24 immunostaining
after interferon administration. Two of the non-responders
showed positive immunostaining for P24 prior to IFN
therapy, and both became negative after IFN.
Two of the four responders had elevated Ki 67 levels
(18-25%), which decreased to low levels after the initiation
of IFNa therapy. Of the three non-responders, only one had
an elevated Ki 67 (19%), which failed to decrease after either
interferon or tamoxifen. This patients was both ER and P24
negative.
Although immunostaining for TGF,8 could be demonstrat-
ed in all patients, levels in ER positive patients were higher
(mean 2,7) than those in ER negative patients (mean 1,5). Of
the four responders, three had no change and one decreased
the degree of staining. All the non-responders decreased
TGFP levels after interferon and or tamoxifen (Table IV).
All of the patients showed positive staining for PDGF aa,
but there was no clear pattern of change after either
interferon or tamoxifen that was correlated with response.
Only two patients had clear positive immunostaining for
PDGF bb, and both of these were responders (IPR, 1CR).
Responding patients thus had a significantly higher level of
PDGF bb than non-responders (1,02 vs 0,2) (Table IV).
When all the variables were examined for an association
with response to treatment only pretreatment ER positivity
and an increase in P24 expression after IFN treatment cor-
related significantly with response (Table V).
Discussion
In vitro studies suggest that the interferons should be useful
in the treatment of breast cancer, modulating both tumour
Table II Toxicity from IFNa and IFNa plus tamoxifen
Worst grade
at any time
Number Per cent (WHO)
Flu-like symptoms 2 29 1
Fever 1 14 1
Hematologic 0 0 0
Table I Patient and biologic determinants and response to treatment with IFN and TMX
PR PDGF aa KI 67 Response to
Age ER H-score P24 TGFP score PDGF bb % treatment
1 25 0 0 100 2 150 0 1 NR
2 39 100 0 100 2 300 2,5 18 PR
3 40 130 125 200 5 400 0 6 PR
4 38 0 0 0 1,5 150 0 19 NR
5 45 130 30 100 2 250 1,5 16 CR
6 46 110 110 120 3 250 0 1 NR
7a 53 125 150 200 2 100 0 1 PR
aPostmenopausal.354 L. SEYMOUR & W.R. BEZWODA
Table III In vivo effect of IFN and TMX on tumour ER and PR expression by
immunocytochemical assay (ICA)
After IFN After addition of TMX
Increase Decrease No change Increase Decrease No change
Responders
ER-ICA 4 0 1 0 2 2
PR-ICA 1 1 2 3 0 1
Non-responders
ER-ICA 1 0 2 0 1 2
PR-ICA 0 1 2 1 0 2
Table IV In vivo effect of IFN and TMX on tumour cell expression. The estrogen
regulated protein P24, the proliferation associated antigen Ki 67 and of two growth
factors
After IFN After addition of TMX
Increase Decrease No change Increase Decrease No change
Responders
P24 4 0 0 0 3 1
Ki 67 0 2 2 0 1 3
TGFP 0 1 3 1 1 2
PDGF 2 1 0 1 2 1
Non-responders
P24 0 2 1 1 0 2
Ki 67 0 0 3 0 0 3
TGF, 0 2 1 0 1 2
PDGF 1 0 2 0 1 2
Table V In vitro biologic predictors of response to treatment with
IFN and TMX
Responders Non-responders
Pretreatment
ER + 4/4 1/3d
Post therapy
p24b 4/4 0/3a
aSignificant at 0,05 Fishers exact probability test). bIncrease
occurring after IFN administration.
cell growth as well as the expression of a number of func-
tional proteins (such as hormone receptors), the expression of
which may, in turn, offer opportunities for the more effective
use of other growth modulating drugs. In this pilot investiga-
tion, alterations in the expression of ER, the estrogen
regulated protein P24, and the proliferation associated
antigen Ki 67, as well as that of two growth factors, PDGF
and TGFP were studied. The changes observed were related
to predictions from in vitro models (Knabbe et al., 1987), as
well as to clinical results.
Serial biopsies showed that ER expression consistently in-
creased after IFN administration. This increase was expected
on the basis of in vitro models (Van den Berg et al., 1987;
Bezwoda & Meyer 1990). In addition the expression of the
estrogen regulated protein P24 [which has been found to
have prognostic importance in breast cancer (Seymour et al.,
1990c)] also showed consistently increased expression in
tumour cells ofresponding patients after IFN administration.
P24 has been shown to be an estrogen regulated secretory
protein (Edwards et al., 1981; Adams et al., 1983; Ciocca et
al., 1984) expressed in hormone receptor positive cell lines as
well as in estrogen responsive target tissues. Because of its
regulation by estrogens it was thought that investigation of
P24 would provide an additional index of the hormone
receptor -new protein synthesis pathway. Although the func-
tional significance of P24 is not fully understood it is thought
to be related to the heat shock protein, hsp 27 (Fuqua et al.,
1990). Whether the alteration in P24 expression was directly
related to IFN therapy or a consequence of increased ER
expression is not certain. Interferons have previously been
reported to directly influence the production of other est-
rogen regulated proteins, e.g. PS 2/BCEJ (Solary et al., 1991)
although in this instance the effects of IFNx are to cause a
reduction of the rate of synthesis of this protein.
In addition to showing the effects of drug treatment on
tumour proteins the present study confirmed the relationship
between P24 and ER. P24 staining was moreover, equivalent
to ER in predicting response, the same patients demons-
trating increments of both ER and P24 and response to
treatment.
The addition to showing the effects of drug treatment on
tumour proteins the present study confirmed the relationship
between P24 and ER. P24 staining was moreover, equivalent
to ER in predicting response, the same patients demons-
trating increments of both ER and P24 and response to
treatment.
The alterations induced by IFN pretreatment on the ex-
pression of the proliferation associated antigen Ki 67, which
has previously been shown to correlate with mitotic index, 'S'
phase fraction and prognosis in breast cancer (Barnard et al.,
1987; Walker & Camplejohn, 1988), were those which were
predicted from the in vitro anti-proliferative effects of IFN.
Both the patients who had initial high Ki 67 expression,
showed significant reduction after IFN and both responded
to therapy.
The in vivo demonstration of PDGF in breast cancer cells
was also of some interest. The presence of both PDGF and
its receptor in a number of soft tissue tumours suggest that
PDGF may have an auto-stimulatory role in the growth of
these cancers (Perosio & Brooks, 1989). PDGF occurs in
three isoforms. While the bb isoform has the most mitogenic
activity, the aa isoform is most commonly observed in
tumours. We have previously demonstrated that increased
plasma levels of PDGF are of prognostic importance in
breast cancer, and that elevated levels correlate with tumour
bulk (Ariad et al., 1991). PDGF aa staining was found to be
positive prior to treatment in the majority of breast cancersINTERFERON PLUS TAMOXIFEN IN BREAST CANCER 355
studied in this investigation, although no correlation could be
found between level of expression and any other variable,
including response to treatment in this small study. PDGF
bb, however, was positive in only 2/7 patients, both of whom
were ER positive and both of whom responded to therapy.
Neither patient showed any significant change in PDGF bb
immunostaining after IFN or IFN and TMX. Although
PDGF has previously been detected in breast cancer cell lines
(Perosio & Brooks, 1989), the present study appears to be the
first in which PDGF has been demonstrated in clinical breast
cancer specimens.
The in vivo pattern of TGFI3 expression was the most
difficult to reconcile with the predictions from the in vitro
models. TGFP has been extensively studied using the hor-
monally responsive MCF-7 cell line as a mode. In the MCF
7 model TMX has been shown to induce both the synthesis
as well as secretion ofTGFi, which then acts as an autocrine
growth inhibitor. Although TGFP has mostly been charac-
terised as an inhibitory growth factor (Knabbe et al., 1987;
Arrick et al., 1990), there is evidence which suggests that
TGFP may also be growth stimulatory to cells derived from
mammary epithelium (Welch et al., 1990). It should also be
pointed out that the majority of patients investigated here
showed easily detectable TGFP immunostaining prior to
treatment. The question thus arises as to why tumours which
demonstrated the presence of an apparently inhibitory
growth factor (TGFIB) have such aggressive and clinically
progressive disease, as had the patients in this study. While it
is possible that functionally active TGF,B levels may not
correlate with TGF-beta immunostaining [since TGF,B has
been shown to exist in a precursor form (Wakefield et al.,
1989), and the mere presence of TGFI3 immunostaining in
cells does not necessarily indicate the presence of active or
secretable growth factor], it should be pointed out that the
antibody used for dection of TGFPi has neutralising activity
and that in our hands, changes in TGF,B immmunostaining
have correlated with the expected increase in synthesis and
secretion of TGFP in MCF 7 cells following treatment with
TMX. It is thus believed that an active form of TGF,B is
being detected although, because of cross reactivity were
unable to distinguish between the TGFPI3, and TGFI32
isoforms. While the changes in TGFP immunostaining fol-
lowing treatment were variable (Table IV), it might be
pointed out that the non-responders all decreased staining
after IFN and/or TMX.
It would appear that for both TGFP and for PDGF, the
relationship between the presence of growth factor in tumour
cells and the influence on tumour growth is probably more
complex than has been appreciated from in vitro studies. The
possibility of multiple interactions between malignant cells
and stromal cells which can both respond to, and in turn
produce their own growth controlling signals (many of which
are probably as yet unidentified) makes it probable that the
end result is a balance between multiple interactions.
From the clinical point of view, it is difficult to draw
conclusions regarding the effectiveness of the combination of
IFN plus tamoxifen as compared to tamoxifen alone. The
prime object of this pilot study was to determine the in vivo
tumour biologic changes resulting from exposure to each of
the drugs. In this regard, while the present study confirmed
the relationship between ER expression and response to
therapy (Bezwoda et al., 1991), it should be pointed out that
responses in 4/7 (57%) occurring in a group of
premenopausal, heavily pretreated patients may well be
higher than expected except among a strongly ER positive
group, and that IFN did significantly increase ER concentra-
tion.
Against this, however, is a previous study by Macheldt and
co-workers (1991) using a combination of IFN and TMX
(either from the outset or by adding IFN to patients not
responding to TMX) which came to the conclusion that IFN
neither contributed to the response rate observed nor was it
able to reverse established TMX resistance. While this ques-
tion remains unresolved the results of the present study show
that IFN (under appropriate conditions) is able to induce in
vivo changes in breast tumour determinants which would be
expected to result in a synergistic effect with tamoxifen.
Moreover, while previous in vitro studies showed that the
effects of IFN on ER content were induced fairly rapidly, the
present in vivo study demonstrates a sustained effect (lasting
for at least 2 weeks) on the increment of ER expression.
Since the present study also showed that some of the
effects of TMX and IFN on tumour cells appeared to be
opposed (with the addition of TMX causing a down-
regulation of both ER and P24) the results may also indicate
that any therapeutic plan aimed at modulation of biologic
influence on tumour cell growth may well have to be app-
roached more subtly than mere empiric combination of the
two agents. The optimum method of combining the two
therapies may well be by the use of alternating periods of
treatment. Such an approach might help to extend the period
of hormonal responsiveness amongst patients whose tumours
are potentially responsive to tamoxifen through the ER
related mechanism of action.
In addition the present study appears to indicate a com-
plex relationship between response to treatment and changes
in growth factor expression, which were variably influenced
by both interferon and by tamoxifen again with sometimes
opposing effects. These studies should caution against a
simplistic model of control of tumour cell proliferation
derived from a single in vitro model and indicate the need for
further research. While such studies may well be complex, the
fact that a number of predictions made from in vitro models
have been able to be tested and confirmed in vivo, points to
the importance of this type of investigation and should pro-
vide a stimulus for further research.
This work was supported by a grant from the National Cancer
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